We demonstrated that LECT2 can inhibit hepatic CSCs expansion by targeting hepatocyte growth factor (HGF)–induced c-MET/GSK3β/β-catenin axis, and this finding provides a novel strategy for HCC management in the future. The gene discussed is MET; the disease is hepatocellular carcinoma.